ArticleInternational urology and nephrology2007
Hepatitis G virus exposure in dialysis patients.
Article in International urology and nephrology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 26 citations in OpenAlex.
- The epidemiology of hepatitis C virus in Iran: Systematic review and meta-analyses.Scientific reports · 2018Pooled it
- Epidemiology of hepatitis C virus among hemodialysis patients in the Middle East and North Africa: systematic syntheses, meta-analyses, and meta-regressions.Epidemiology and infection · 2017Pooled it
- Oncogenic Viral Infections Among Iranian Hemodialysis Patients: A Systematic Review.International journal of preventive medicine · 2019Article
- Prevalence of hepatitis C infection in Iranian hemodialysis patients: An updated systematic review and meta-analysis.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2017Review
- Hepatitis C and G Virus Infection Prevalence Among Hemodialysis Patients and Associated Risk Factors in the Hormozgan Province of Southern Iran.Hepatitis monthly · 2016Article
- Isolated anti-hbc and occult HBV infection in dialysis patients.Nephro-urology monthly · 2015Article
- Evaluation of prevalence and risk factors of hepatitis g virus infection among hemodialysis patients referred to Iranian army hospitals in tehran during 2012-2013.Hepatitis monthly · 2015Article
- Hepatitis G virus exposure in dialysis patients and blood donors in Isfahan-Iran.International journal of preventive medicine · 2014Article
- GB virus C Viremia and Anti-E2 Antibody Response Among Hemodialysis Patients in Gorgan, Iran.Jundishapur journal of microbiology · 2014Article
- Screening of Hepatitis G and Epstein-Barr Viruses Among Voluntary non Remunerated Blood Donors (VNRBD) in Burkina Faso, West Africa.Mediterranean journal of hematology and infectious diseases · 2013Article
- Hepatitis G virus infection in Egyptian children with chronic renal failure (single centre study).Annals of clinical microbiology and antimicrobials · 2009Article
- Use of genetic immunization to generate a high-level antibody against rat dicarboxylate transporter.International urology and nephrology · 2009Article
- The promising future of long-term peritoneal dialysis.International urology and nephrology · 2008Article
- Our war against bacteria in peritoneal dialysis, the last 40 years!International urology and nephrology · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatitis G virus (HGV) is a blood-borne virus. The predominant route of its transmission is parenteral. The aim of this study was to assess the frequency of HGV exposure in haemodialysis (HD) and continuous ambulatory peritoneal dialysis (CAPD) patients in Iran.
methodsThis study was performed in a major dialysis centre in Tehran, Iran. The study cohort consisted of 77 patients on HD and 13 patients on CAPD. The presence of anti-HGV envelope protein E2 (anti-E2) in the blood serum, as determined by means of an ELISA assay, indicated HGV exposure. All patients were also screened for hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (anti-HBs) and hepatitis C antibody (anti-HCV). In patients who tested positive for anti-E2, HGV RNA was detected by RT-PCR using primers derived from the NS5A region of the viral genome.
resultsIn total, 3.89% of the HD patients and none of the CAPD patients tested positive for anti-E2. None of the patients tested positive for HGV RNA. The mean age of the anti-E2-positive patients was 53.3 +/- 26.5 years, with 66.66% having previously received blood transfusion. The mean duration of dialysis of the anti-E2-positive patients was 68 +/- 64 months. Co-infection with HCV or HBV was not observed in the anti-E2 positive patients.
conclusionThe rate of exposure to HGV was low among the dialysis patients in our study. The appearance of anti-E2 was accompanied by clearance of serum HGV-RNA. No relationship was noted between HGV exposure and age, sex, history of blood transfusion, time on dialysis and HCV or HBV markers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.